Biopharma & Life Sciences
Roivant Sciences Executive Compensation (FY24)
ROIV · Executive and director compensation, fiscal 2022 to 2024
Data as of September 7, 2026Latest filing (DEF 14A): July 29, 2026
217 figures on this page: 215 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Total compensation for Matthew Gline, Chief Executive Officer, came to $163,293,744 in fiscal 2024, and Gline's total was up from the $738,189 reported for fiscal 2023. The company reported a chief executive pay ratio of 518:1 for fiscal 2024, against median employee compensation of $315,444. For fiscal 2024, shareholders backed the say-on-pay proposal with 60.9% of votes cast for or against in favor at the meeting held September 10, 2025. The disclosed peer group names ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc. and Ascendis Pharma, Inc., among others.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Matthew Gline: $738,189 → $163,293,744
Frequently asked questions
Answers drawn from the data on this page.
Who is Roivant Sciences' chief executive and what were they paid?
Total compensation for Matthew Gline, Chief Executive Officer, came to $163,293,744 in fiscal 2024. Gline's total was up from the $738,189 reported for fiscal 2023.
What was Roivant Sciences' say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 60.9% of votes cast for or against in favor at the meeting held September 10, 2025.
Which companies are in Roivant Sciences' peer group?
The disclosed peer group names ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc. and Ascendis Pharma, Inc., among others.
What is Roivant Sciences' chief executive pay ratio?
The company reported a chief executive pay ratio of 518:1 for fiscal 2024, against median employee compensation of $315,444.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Matthew Gline Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Mayukh Sukhatme President and Chief Investment Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Eric Venker President and Immunovant CEO | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Richard Pulik Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Rakhi Kumar Former Chief Accounting Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Matthew Gline Chief Executive Officer | ◇ | — | — | — | — | — | ◇ | ◇ |
Eric Venker President and Immunovant CEO | ◇ | — | — | — | — | — | ◇ | ◇ |
Mayukh Sukhatme President and Chief Investment Officer | ◇ | — | — | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mayukh Sukhatme President and Chief Investment Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Matthew Gline Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Eric Venker President and Immunovant CEO | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Rakhi Kumar Former Chief Accounting Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Richard Pulik Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Jennifer Humes Chief Accounting Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Eric Venker | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Eric Venker | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jennifer Humes | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jennifer Humes | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Matthew Gline | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mayukh Sukhatme | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Rakhi Kumar | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Rakhi Kumar | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Richard Pulik | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Richard Pulik | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Mayukh Sukhatme | Option | ◇ | — | ◇ | 4/19/2032 |
| Option | ◇ | — | ◇ | 5/19/2029 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/1/2031 | |
| Richard Pulik | Option | ◇ | — | ◇ | 4/19/2033 |
| Option | ◇ | — | ◇ | 4/19/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/21/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 10/19/2031 | |
| Jennifer Humes | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 3/19/2035 | |
| Rakhi Kumar | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/19/2032 | |
| Option | ◇ | — | ◇ | 4/19/2033 | |
| Option | ◇ | — | ◇ | 5/1/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/21/2034 | |
| Matthew Gline | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/1/2031 | |
| Option | ◇ | — | ◇ | 4/19/2032 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/1/2031 | |
| Eric Venker | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 7/25/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/19/2032 | |
| Option | ◇ | — | ◇ | 5/1/2031 | |
| Option | ◇ | — | ◇ | 5/1/2031 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Ilan Oren | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Melissa Epperly | ◇ | ◇ | ◇ | — | — | — | ◇ |
Daniel Gold | ◇ | ◇ | ◇ | — | — | — | ◇ |
Meghan FitzGerald | ◇ | ◇ | ◇ | — | — | — | ◇ |
Keith Manchester | ◇ | ◇ | ◇ | — | — | — | ◇ |
James C. Momtazee | ◇ | ◇ | ◇ | — | — | — | ◇ |
Matthew Gline and Mayukh Sukhatme served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as RSUs and Stock Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ACADIA Pharmaceuticals Inc. ACAD
- Amicus Therapeutics, Inc. FOLD
- Apellis Pharmaceuticals, Inc. APLS
- Arcutis Biotherapeutics, Inc. ARQT
- Ascendis Pharma, Inc. ASND
- Axsome Therapeutics, Inc. AXSM
- Blueprint Medicines Corporation BPMC
- BridgeBio Pharma, Inc. BBIO
- Cerevel Therapeutics Holdings, Inc. CERE
- CRISPR Therapeutics, Inc. CRSP
- Denali Therapeutics Inc. DNLI
- Exelixis, Inc. EXEL
- Halozyme Therapeutics, Inc. HALO
- ImmunoGen, Inc. IMGN
- Incyte Corporation INCY
- Intra-Cellular Therapies, Inc. ITCI
- Ionis Pharmaceuticals, Inc. IONS
- Jazz Pharmaceuticals, Inc. JAZZ
- Karuna Therapeutics, Inc. KRTX
- MoonLake Immunotherapeutics MLTX
- Neurocrine Biosciences Inc. NBIX
- Revolution Medicines, Inc. RVMD
- Sarepta Therapeutics, Inc. SRPT
- United Therapeutics Corporation UTHR
- Vaxcyte, Inc. PCVX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | September 10, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | September 10, 2024 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Roivant Sciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Roivant Sciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Roivant Sciences recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
217 figures on this page: 215 cited to the filing that reported them, 2 calculated from figures it prints.
215 cited to the filing
2 calculated from the filing
Documents cited
- 0001140361-26-029955Director Compensation
- 0001140361-25-034711Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-25-027846Director Compensation Table for Fiscal 2024 · Grants of Plan-Based Awards for Fiscal 2024 · Outstanding Equity Awards at 2024 Fiscal Year End · Outstanding Equity Awards at Fiscal Year End · and 2 more sections
- 0001140361-24-041188Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-24-034423Summary Compensation Table
- 0001140361-23-037044Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Roivant Sciences executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/ROIV (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Roivant Sciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Roivant Sciences discloses
The companies named in ROIV's own disclosed peer group.
ACADIA Pharmaceuticals Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.Arcutis Biotherapeutics, Inc.BridgeBio Pharma, Inc.CRISPR Therapeutics, Inc.Denali Therapeutics Inc.Exelixis, Inc.Halozyme Therapeutics, Inc.Incyte CorporationIonis Pharmaceuticals, Inc.Jazz Pharmaceuticals, Inc.Neurocrine Biosciences Inc.Sarepta Therapeutics, Inc.United Therapeutics CorporationVaxcyte, Inc.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}